MeVac-Meilahti Vaccine Research center

The MeVac-Meilahti Vaccine Research center conducts studies to define the safety profile of novel pneumococcal vaccines aimed at preventing bacterial infections.

• Safety profiling in healthy infants
• Tolerability assessment in children
• Monitoring of adverse events

These trials seek to confirm that the vaccine is well‑tolerated before it can be considered for broader public health use.

Research at the Helsinki site evaluates the immune response generated by the experimental PG4 vaccine targeting pneumococcal disease.

• Immunogenicity in healthy adolescents
• Antibody development patterns
• Cellular immunity assessment

By understanding how the body reacts, investigators aim to guide future improvements in vaccine design and efficacy.